Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.
Gastric Cancer
DRUG: Apatinib|DRUG: Docetaxel
Progression free survival, 6 months
This trial investigated the safety and efficacy of apatinib plus docetaxel, as a treatment option for heavily pretreated patients with advanced gastric cancer.